Login to Your Account



Clinic Roundup


Monday, August 20, 2012
• Evolva Holdings SA, of Reinach, Switzerland, said top-line results for the first 32 patients enrolled in the Phase IIa study testing EV-077, a reversible antagonist of isoprostanes and prostanoids, showed promising efficacy, indicating that the drug, when given orally twice daily to patients with Type II diabetes, provided antiplatelet activity, reduced exercise-induced proteinuria and increased forearm blood flow.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription